Effects of chronic trimetazidine treatment on myocardial preconditioning in anesthetized rats

Fundamental and Clinical Pharmacology

Volumn 20, Issue 5, 2006, Pages 449-459

  Kara, Ali F ^a   Demiryürek, Şeniz ^b   Çelik, Ahmet ^a   Tarakçioǧlu, Mehmet ^a   Demiryürek, Abdullah T ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Arrhythmias; Carbachol; Infarct size; Preconditioning; Trimetazidine

Indexed keywords

CARBACHOL; LACTIC ACID; MALONALDEHYDE; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; ISCHEMIC PRECONDITIONING; LACTATE BLOOD LEVEL; MALE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; TREATMENT DURATION;

ANIMALS; BLOOD PRESSURE; CARBACHOL; CARDIOTONIC AGENTS; HEART RATE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LACTIC ACID; MALE; MALONDIALDEHYDE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; TACHYCARDIA, VENTRICULAR; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FIBRILLATION;

EID: 33748697049     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2006.00426.x     Document Type: Article

References (38)

1. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The anti-anginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. (2000) 86 580-588.
2. Jackson G. Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents. Int. J. Clin. Pract. (2001) 55 256-261.
3. Stanley W.C., Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam. Clin. Pharmacol. (2003) 17 133-145.
4. Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron. Artery Dis. (2004) 1 S17-S21.
5. Vitale C., Wajngaten M., Sposato B. et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J. (2004) 20 1814-1821.
6. Blardi P., de Lalla A., Volpi L., Auteri A., Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol. Res. (2002) 45 69-72.
7. Kara A.F., Demiryurek S., Celik A., Tarakcioglu M., Demiryurek A.T. Effects of trimetazidine on myocardial preconditioning in anesthetized rats. Eur. J. Pharmacol. (2004) 503 135-145.
8. Elimadi A., Settaf A., Morin D. et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J. Pharmacol. Exp. Ther. (1998) 286 23-28.
9. Yamaguchi F., Nasa Y., Yabe K. et al. Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart. Heart Vessels (1997) 12 74-83.
10. Walker M.J.A., Curtis M.J., Hearse D.J. et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc. Res. (1988) 22 447-455.
11. Demiryurek A.T., Yildiz G., Esiyok S., Altug S. Protective effects of poly (ADP-ribose) synthase inhibitors on digoxin-induced cardiotoxicity in guinea-pig isolated hearts. Pharmacol. Res. (2002) 45 189-194.
12. Komori S., Ishii M., Hashimoto K. Antiarrhythmic effects of coronary vasodilators on canine ventricular arrhythmia models. Jpn. J. Pharmacol. (1985) 38 73-82.
13. Pisarenko O.I., Shulzhenko V.S., Studneva I.M. Metabolic and functional effects of carbachol-induced and ischaemic preconditioning in rat isolated heart. Clin. Exp. Pharmacol. Physiol. (1999) 26 26-31.
14. ATP channels in rat heart: blockade of ischemic and acetylcholine-mediated preconditioning by glibenclamide. Am. J. Physiol. (1996) 271 H23-H28.
15. Minners J., van den Bos E.J., Yellon D.M., Schwalb H., Opie L.H., Sack M.N. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc. Res. (2000) 47 68-73.
16. Drake-Holland A.J., Belcher P.R., Hynd J., Noble M.I. Infarct size in rabbits: a modified method illustrated by the effects of propranolol and trimetazidine. Basic Res. Cardiol. (1993) 88 250-258.
17. Noble M.I., Belcher P.R., Drake-Holland A.J. Limitation of infarct size by trimetazidine in the rabbit. Am. J. Cardiol. (1995) 76 41B-44B.
18. Murnaghan M.F. Effect of fatty acids on the ventricular arrhythmia threshold in the isolated heart of the rabbit. Br. J. Pharmacol. (1981) 73 909-915.
19. d'Alche P., Clauser P., Morel M., Gauthier V. Assessment with potential mapping of the cardiac protective effect of a drug. Example of trimetazidine. J. Pharmacol. Methods (1991) 26 43-51.
20. Libersa C., Honore E., Adamantidis M., Rouet E., Dupuis B. Antiischemic effect of trimetazidine: enzymatic and electric response in a model of in-vitro myocardial ischemia. Cardiovasc. Drugs Ther. (1990) 4 808-809.
21. 31P-NMR spectroscopy in the isolated rat heart. Arch. Int. Pharmacodyn. Ther. (1987) 286 97-110.
22. Aussedat J., Ray A., Kay L., Verdys M., Harpey C., Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J. Cardiovasc. Pharmacol. (1993) 21 128-135.
23. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc. Drugs. Ther. (1988) 1 677-686.
24. El Banani H., Bernard M., Baetz D. et al. Changes in intracellular sodium and pH during ischemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischemia. Cardiovasc. Res. (2000) 47 688-696.
25. 3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br. J. Pharmacol. (1998) 123 1385-1394.
26. Fantini E., Athias P., Demaison L., Grynberg A. Protective effects of trimetazadine on pHi regulation in hypoxic cardiac myocytes from the rat. Fundam. Clin. Pharmacol. (1979) 11 427-439.
27. Williams F.M., Tanda K., Kus M., Williams T.J. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J. Cardiovasc. Pharmacol. (1993) 22 828-833.
28. Fabiani J.N., Ponzio O., Emerit I. et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J. Cardiovasc. Surg. (1992) 33 486-491.
29. 2 from DNA damage. Free Radic. Biol. Med. (2001) 30 1357-1364.
30. Tetik C., Ozden A., Calli N. et al. Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischemia-reperfusion injury in rats. Transplant. Int. (1999) 12 108-112.
31. Tikhaze A.K., Lankin V.Z., Zharova E.A., Kolycheva S.V. Trimetazidine as indirect antioxidant. Bull. Exp. Biol. Med. (2000) 10 951-953.
32. Maupoil V., Rochette L., Tabard A., Clauser P., Harpey C. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: effect of trimetazidine. Adv. Exp. Med. Biol. (1990) 264 373-376.
33. Ancerewicz J., Migliavacca E., Carrupt P.A. et al. Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants. Free Radic. Biol. Med. (1998) 25 113-120.
34. Monteiro P., Duarte A.I., Goncalves L.M., Moreno A., Providencia L.A. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia. Eur. J. Pharmacol. (2004) 503 123-128.
35. Guarnieri C., Finelli C., Zini M., Muscari C. Effects of trimetazidine on the calcium transport and oxidative phosphorylation of isolated rat heart mitochondria. Basic Res. Cardiol. (1997) 92 90-95.
36. ATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart. J. Mol. Cell. Cardiol. (1997) 29 1055-1060.
37. Birand A., Kudaiberdieva G.Z., Batyraliev T.A., Akgul F., Usal A. Effect of TMZ on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology (1997) 48 413-422.
38. Ulgen M.S., Akdemir O., Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int. J. Cardiol. (2001) 77 255-262.